SFlt-1 elevates blood pressure by augmenting endothelin-1-mediated vasoconstriction in mice

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Amraoui, Fouad ^a   Spijkers, Léon ^a   Lahsinoui, Hajar Hassani ^a   Vogt, Liffert ^a   Van Der Post, Joris ^a   Peters, Stephan ^a   Afink, Gijs ^a   Ris Stalpers, Carrie ^a   Van Den Born, Bert Jan ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENDOTHELIN 1; INDOMETACIN; PICOTAMIDE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; THROMBOXANE A2; THROMBOXANE SYNTHASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC HYPERTENSION; ARTICLE; BLOOD PRESSURE MEASUREMENT; CAROTID ARTERY; CONTROLLED STUDY; DOWN REGULATION; DRUG OVERDOSE; DRUG TARGETING; ENZYME INHIBITION; EX VIVO STUDY; HYPERTENSION; ISOLATED ORGAN; MALE; MEAN ARTERIAL PRESSURE; MESENTERIC ARTERY; MOUSE; MOUSE MODEL; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEINURIA; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; BLOOD PRESSURE; CAROTID ARTERIES; ENDOTHELIN-1; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, ENDOTHELIN; RNA, MESSENGER; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASOCONSTRICTION;

EID: 84897983668     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091897     Document Type: Article

References (39)

1. Powe CE, Levine RJ, Karumanchi SA (2011) Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123: 2856-2869.
2. Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49: 186-193. (Pubitemid 46178407)
3. Maynard SE, Min JY, Merchan J, Lim KH, Li J, et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658.
4. Jebbink J, Keijser R, Veenboer G, van der Post J, Ris-Stalpers C, et al. (2011) Expression of placental FLT1 transcript variants relates to both gestational hypertensive disease and fetal growth. Hypertension 58: 70-76.
5. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683. (Pubitemid 38364626)
6. Bridges JP, Gilbert JS, Colson D, Gilbert SA, Dukes MP, et al. (2009) Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertens 22: 564-568.
7. Li F, Hagaman JR, Kim HS, Maeda N, Jennette JC, et al. (2012) eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype. J Am Soc Nephrol 23: 652-660.
8. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, et al. (2010) Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 56: 675-681.
9. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, et al. (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136. (Pubitemid 351398487)
10. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM (2009) Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54: 652-658.
11. Murphy SR, LaMarca B, Cockrell K, Arany M, Granger JP (2012) L-arginine supplementation abolishes the blood pressure and endothelin response to chronic increases in plasma sFlt-1 in pregnant rats. Am J Physiol Regul Integr Comp Physiol 302: R259-R263.
12. George EM, Granger JP (2011) Endothelin: key mediator of hypertension in preeclampsia. Am J Hypertens 24: 964-969.
13. Taylor RN, Varma M, Teng NN, Roberts JM (1990) Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab 71: 1675-1677. (Pubitemid 120032795)
14. Murphy SR, LaMarca BB, Cockrell K, Granger JP (2010) Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 55: 394-398.
15. Kappers MH, Smedts FM, Horn T, van Esch JH, Sleijfer S, et al. (2011) The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 58: 295-302.
16. Takayasu-Okishio M, Terashita Z, Kondo K (1990) Endothelin-1 and platelet activating factor stimulate thromboxane A2 biosynthesis in rat vascular smooth muscle cells. Biochem Pharmacol 40: 2713-2717.
17. D'Orleans-Juste P, Claing A, Telemaque S, Maurice MC, Yano M, et al. (1994) Block of endothelin-1-induced release of thromboxane A2 from the guinea pig lung and nitric oxide form the rabbit kidney by a selective ETB receptor antagonist, BQ-788. Br J Pharmacol 113: 1257-1262. (Pubitemid 24364407)
18. Mills JL, DerSimonian R, Raymond E, Morrow JD, Roberts LJ, et al. (1999) Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. JAMA 282: 356-362. (Pubitemid 29350490)
19. Mousa AA, Strauss JF, III, Walsh SW (2012) Reduced methylation of the thromboxane synthase gene is correlated with its increased vascular expression in preeclampsia. Hypertension 59: 1249-1255.
20. Spijkers LJ, Janssen BJ, Nelissen J, Meens MJ, Wijesinghe D, et al. (2011) Antihypertensive treatment differentially affects vascular sphingolipid biology in spontaneously hypertensive rats. PLoS One 6: e29222.
21. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9: 671-675.
22. Dekker GA, Kraayenbrink AA, Zeeman GG, van Kamp GJ (1991) Increased plasma levels of the novel vasoconstrictor peptide endothelin in severe pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 40: 215-220.
23. Nova A, Sibai BM, Barton JR, Mercer BM, Mitchell MD (1991) Maternal plasma level of endothelin is increased in preeclampsia. Am J Obstet Gynecol 165: 724-727.
24. Hood JD, Meininger CJ, Ziche M, Granger HJ (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274: H1054-H1058.
25. Cardillo C, Kilcoyne CM, Cannon RO, III, Panza JA (2000) Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 35: 1237-1241. (Pubitemid 30413657)
26. Faxen M, Nisell H, Kublickiene KR (2000) Altered gene expression of endothelin-A and endothelin-B receptors, but not endothelin-1, in myometrium and placenta from pregnancies complicated by preeclampsia. Arch Gynecol Obstet 264: 143-149.
27. Karaki H, Sudjarwo SA, Hori M (1994) Novel antagonist of endothelin ETB1 and ETB2 receptors, BQ-788: effects on blood vessel and small intestine. Biochem Biophys Res Commun 205: 168-173.
28. Costantine MM, Tamayo E, Lu F, Bytautiene E, Longo M, et al. (2010) Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol 116: 114-120.
29. Bergmann A, Ahmad S, Cudmore M, Gruber AD, Wittschen P, et al. (2010) Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 14: 1857-1867.
30. Suzuki H, Ohkuchi A, Matsubara S, Takei Y, Murakami M, et al. (2009) Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension 54: 1129-1135.
31. Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, et al. (2008) Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 21: 1288-1291.
32. Abdalvand A, Morton JS, Bourque SL, Quon AL, Davidge ST (2013) Matrix metalloproteinase enhances big-endothelin-1 constriction in mesenteric vessels of pregnant rats with reduced uterine blood flow. Hypertension 61: 488-493.
33. Makris A, Thornton C, Thompson J, Thomson S, Martin R, et al. (2007) Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 71: 977-984. (Pubitemid 46741987)
34. White RM, Rivera CO, Davison CB (1996) Differential contribution of endothelial function to vascular reactivity in conduit and resistance arteries from deoxycorticosterone-salt hypertensive rats. Hypertension 27: 1245-1253. (Pubitemid 26165626)
35. Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH (2013) Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertens 31: 444-454.
36. Kandula P, Agarwal R (2011) Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int 80: 1271-1277.
37. Pereg D, Lishner M (2008) Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword? Eur Heart J 29: 2325-2326.
38. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA (2007) Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369: 1791-1798. (Pubitemid 46782996)
39. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23: 460-468.